Bioporto A/s · OMXCOP:BIOPOR
Bioporto A/s — Q3 2022 Earnings Presentation
17 slides from Bioporto A/s's earnings presentation, Nov 9, 2022
Slide 1: Empowering Early Detection of Kidney Injury
Empowering Early Detection of Kidney Injury 2022-Q3 Financial Results & Business Update November 9, 2022 © Copyright BioPorto | 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matte
Slide 3: Highlights from Q3 2022
Highlights from Q3 2022 • Data for FDA submission for the NGAL Test is being compiled and analyzed – subject to ongoing review, it remains on track for Q4 2022 • Solid financial performance – YTD revenue up 16% over 2021 • Controlled commercialization costs – modifying EBIT and Adjusted EBITDA guida
Slide 4: We save lives and improve quality of life with actionable biomarkers
We save lives and improve quality of life with actionable biomarkers In 2022-2023 we will Launch an FDA Cleared Product in the US Drive Market Adoption of the NGAL Test & have a Pipeline of Products that Deliver High Medical Value Strengthen the Company to Scale & Execute Attract, Develop & Retain t
Slide 5: Go-To-Market approach will leverage regional resources of Partners
Go-To-Market approach will leverage regional resources of Partners Core Services Global Market Access Services o Licensing o Medical Education o Product Development o HEOR Studies o Regulatory Filings o Market Development o Intellectual Property o Reimbursement o Manufacturing Engaged Open Channel M
Slide 6: Critical care-focused product development pipeline
Critical care-focused product development pipeline New Product Development Product Feasibility Development Trial Execution Regulatory Approval Commercialization The NGAL Test (automated core lab) NGALds (rapid test) Endothelial damage (thrombomodulin) Undisclosed marker for infection NGAL Test Gen 2
Slide 7: AKI: Abrupt loss of kidney function
AKI: Abrupt loss of kidney function • Today, subclinical in its early Spectrum of Patient Care stages Preventative Restorative 000 Palliative • Preventable and treatable if detected early, but 70% of clinicians believe they are missing AKI • Often occurs in hospitalized patients, particularly those
Slide 8: The NGAL Test saves lives by detecting AKI earlier
The NGAL Test saves lives by detecting AKI earlier Empowers clinicians to manage fluids & nephrotoxic drugs, and determine if dialysis is needed • NGAL: Neutrophil Gelatinase-Associated Lipocalin • Critical care biomarker protein expressed in proximal and distal nephron tubules within the kidney • U
Slide 9: Current method, Serum Creatinine (sCr), is delayed and non-specific
Current method, Serum Creatinine (sCr), is delayed and non-specific In a multicenter prospective study of over 500 biopsy-diagnosed cases of moderate to severe AKI, sCr only properly identified 26% of patients1 Delayed and Dampened Non-specific for AKI Confounded by Other Factors Does not rise until
Slide 10: NGAL for differential diagnosis and therapy of cirrhosis patients with AKI
NGAL for differential diagnosis and therapy of cirrhosis patients with AKI1 Published September 2022 • Cirrhosis can coincide with AKI and complicates diagnoses Conclusions • NGAL used to discriminate different etiologies of AKI (Acute Tubular vs. Hepatorenal Syndrome Necrosis) in cirrhosis “ uNGAL
Slide 11: Effective AKI intervention requires an early indication of kidney injury
Effective AKI intervention requires an early indication of kidney injury1 Initiation: vasoconstriction, Extension: apoptosis and Maintenance: ongoing injury, ATP depletion, oxidant and necrosis, inflammatory dedifferentiation, regeneration, 350 labile iron generation response repair 300 250 NGAL ng/
Slide 12: BioPorto has grown revenue by 16% YTD over 2021
BioPorto has grown revenue by 16% YTD over 2021 Revenue by Quarter YTD Revenue by Product Group 2021 NGAL Tests Antibodies Others 2022 8.5 9.7 6.6 6.8 9.0 6.5 8.5 5.6 Q3 5.3 5.3 7.1 Q3 Q3 Q3 Q2 Q2 Q2 Q2 1.9 1.6 Q1 Q1 Q1 Q3 Q3 Q1 Q1 Q2 Q3 Q4 2021 2022 2021 2022 2021 2022 amounts in DKKm © Copyright B
Slide 13: NGAL test sales up 15% YTD over 2021
NGAL test sales up 15% YTD over 2021 NGAL test sales by Quarter (LTM, DKKm) Global NGAL 15% XX% +68% NGAL 14.1 13.7 13.4 13.5 13.6 13.213.3 12.1 12.0 12.1 11.3 Growth in global YTD NGAL 10.5 test sales over 2021 9.6 9.4 9.5 © Copyright BioPorto | 13
Slide 14: Solid cash position and working capital management
Solid cash position and working capital management Adjusted EBITDA and cash position (DKKm) Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 • YTD’22 cash burn from operations: Adj. EBITDA 107.9 DKKm 35.9, a 29% reduction vs. YTD’21 98.9 Cash position from favorable working capital management 59.6 • Cash bal
Slide 15: Guidance for 2022 adjusted to reflect timing of costs
Guidance for 2022 adjusted to reflect timing of costs Amounts in millions of Danish Kroner and US Dollars1 Actual at 2022 Guidance Sept. 30, 2022 EBIT loss Revenue Cash2 Adj. EBITDA loss DKK 24-27 DKK (83)-(88) DKK (71)-(75) DKK 99 [previously DKK (95)-(100)] [previously DKK (76)-(81)] $3.1-3.5 $(10
Slide 16: Investment Thesis: The first meaningful Acute Kidney Injury (AKI) test
Investment Thesis: The first meaningful Acute Kidney Injury (AKI) test Clinicians are demanding and using The NGAL Test -- a better kidney injury diagnostic The NGAL Test™ saves kidneys & lives with AKI detection when the injury is clinically silent Serves a $3B+ global Market Opportunity in AKI as
Slide 17: Investor Relations Contacts
Investor Relations Contacts CPH:BIOPOR EU: Tim Eriksen US: Ashley Robinson Managing Partner Managing Director Zenith Advisory LifeSci Advisors investor@bioporto.com arr@lifesciadvisors.com +45 4529 0000 +1 617 430 7577 © Copyright BioPorto | 17